Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance study of oral [14C]-IPN60130 in healthy male participants
NL-OMON50811Phase 1Completed
- Sponsor
- Ipsen
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fidrisertib in fibrodysplasia ossificans progressiva (FOP), sponsored by Ipsen. Primary endpoints: Pharmacokinetics of total 14C radioactivity in whole blood and plasma, Mass balance, metabolism, and elimination pathways of [14C] IPN60130 and 1 more. Started Jul 2021; status: completed.
02
Drugs
Fidrisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NL-OMON50811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50811.